Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Date:9/17/2009

ment of squamous cell carcinoma of the head and neck (SCCHN), adult glioma and pediatric glioma. The approval was granted to Laboratorios PiSA in Guadalajara, Mexico and nimotuzumab will be commercialized under the name VECTHIX(R).

    First patients enrolled in multinational randomized, double-blind brain
    metastases trial

YM BioSciences recently enrolled and treated the first two patients in its multinational randomized, double-blind trial evaluating nimotuzumab plus whole-brain radiation therapy (WBRT) to WBRT alone in patients with brain metastases from NSCLC. The trial is designed enroll approximately 88 patients over twelve months followed by a twelve-month follow-up period and will likely include 12 investigational centers in Canada plus additional centers in other countries. The patients were enrolled at the L'Hopital Maisonneuve-Rosemont in Montreal, Canada.

Nimotuzumab (200 mg IV infusions) will be administered weekly during radiotherapy and following radiotherapy until disease progression, unacceptable toxicity or at the discretion of the physician. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day. Patients will be assessed by laboratory tests, imaging studies, standardized neurologic examination, and neurologic symptoms. The primary efficacy endpoint is intracranial disease progression over six months. The secondary endpoints are overall survival (OS); time to neurologic progression (TNP) or death with evidence of neurologic progression; OS rate at six months; time to intracranial disease progression; and time to overall progression.

"This randomized, double-blinded, multicentric trial was based on a randomized pilot open-label trial from which encouraging, preliminary results were presented at the EORTC-NCI-AACR "Molecular Targets and Cancer Therapeutics" meeting held on October 21-24, 2008 in Geneva. YM is preparing to imminently open the first international centers on both th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
5. Cell Biosciences Signs Agreement to Acquire Alpha Innotech
6. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
7. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
10. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
11. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MESA, Calif. , July 24, 2014  Now ... close to home. Rehealth Regenerative Therapies , located ... athletes and other physically active people a new health ... Regardless of age, countless patients suffer from ... sport activities, such as muscle tears, torn rotator cuff, ...
(Date:7/24/2014)... by group leader Yung-Eun Sung has announced that ... and nitrogen-doped graphenes which can be applied as ... cells. Yung-Eun Sung is both a group leader ... for Basic Science* (IBS) and a professor at ... great significance with regards to the development of ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... , SOUTHAMPTON, Pa., Jan. 11 Argyce LLC, the trustee ... will divest the remaining drug development program assets of Genaera ... bids to be received no later than February 12, 2010 ... combination. Any person interested in purchasing the assets or learning ...
... PAREXEL International Corporation (Nasdaq: PRXL ) today raised its ... 2010 ended December 31, 2009, and for the full Fiscal ... financial guidance takes into account the projected impact from second ... amount and timing of a previously announced restructuring charge, and ...
... 7 ... , ... -- Genedata, a leading provider of advanced software solutions for drug discovery and life science ... experienced unprecedented industry adoption with 7 out of the 25 leading pharmaceutical companies using Screener ...
Cached Biology Technology:Genaera Liquidating Trust To Sell Remaining Proprietary Assets 2PAREXEL Issues Updated Financial And Operational Information 2PAREXEL Issues Updated Financial And Operational Information 3PAREXEL Issues Updated Financial And Operational Information 4PAREXEL Issues Updated Financial And Operational Information 5Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 2Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 3
(Date:7/24/2014)... where electric cars ply silent freeways, solar panels blanket ... the earth, from howling winds and from the blazing ... it is technically and economically feasible to convert California,s ... energy. Published in Energy , the plan shows ... supply in California that could create tens of thousands ...
(Date:7/24/2014)... of researchers has developed a new nanoscale agent for ... for assessing the function and properties of the GI ... and treatment of gut diseases. , Illnesses ... and inflammatory bowel disease all occur in the intestine ... with diseases such as diabetes and Parkinson,s. , ...
(Date:7/24/2014)... this week for an all-day public forum on a ... (EPA) to dredge toxic sediment from an eight-mile stretch ... called the plan, which proposes removing 4.3 million cubic ... riverbed, one of the largest cleanups in the agency,s ... off-site. , "We need to ensure the future well-being ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... genomic DNA around nucleosomes in the cell nucleus makes ... (LMU) in Munich now describes a mechanism that allows ... transcription. In higher organisms the genomic DNA is ... called nucleosomes, each consisting of two pairs of four ...
... new report from the Institute of Medicine says schools should ... minutes of vigorous or moderate intensity activity during each school ... current evidence-based guidelines of at least an hour of vigorous ... which was released today. "Because children are in ...
... world,s largest and fastest growing open-access publishers, announces the ... and Biotechnology . A broad scope journal ... will provide a single open-access platform for diverse ... and discussed. Frontiers in Bioengineering and ...
Cached Biology News:Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Request Info...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
Biology Products: